Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Specialty Devices
Cardiovascular Devices
Return to: MDBR Home | Specialty Devices | Cardiovascular Devices

iSchemaView’s cerebrovascular 3D imaging solution wins FDA approval

MDBR Staff Writer Published 02 May 2018

The US Food and Drug Administration (FDA) has approved iSchemaView’s 3D imaging solution for computed tomography angiography.

Dubbed RAPID CTA, the solution identifies regions with reductions in blood flow that can indicate a large vessel occlusion within minutes.

The solution joins the company’s fully-automated imaging devices such as RAPID CTP and RAPID MRI to facilitate clinical decision-making for cerebrovascular diseases like stroke.

The CTA provides physicians with visualizations of blood vessels in the brain, through an injectable contrast agent, X-ray imaging and computer analysis.

iSchemaView said a CT angiogram offers physicians with detailed and accurate images of the vasculature and interpreting standard CTA output is a cumbersome time-consuming process.

The RAPID CTA provides clear maps with colored overlay that identifies brain regions with reduced blood vessel density.

Reduction severity of blood vessels can be visualized via a four-color-coded scale, and physicians can see a 3D reconstruction of vasculature that can be rotated and analyzed from several angles.

The solution also offers remote viewing for physicians in the hospital, at home or on the road. The RAPID CTA image maps are immediately available to doctors via email for viewing on any device, PACS and a web browser. 

iSchemaView CEO Don Listwin said with new FDA clearance and the release of RAPID CTA, the company is making progress on its goal to provide healthcare professionals around the world with the most comprehensive and intuitive suite of imaging solutions possible,” said

Listwin said: “We ensure physicians can take advantage of RAPID’s power whether they choose plain CT, CT Angiography, CT Perfusion or MR diffusion and perfusion. It’s all about offering them the right imaging solution choice, for the right patient at the right time.”

Last month, iSchemaView said that its RAPID advanced imaging technology is being adopted by more than 350 stroke centers to assist physicians in the analysis of brain images using automated tools for CT, CT Perfusion, MR diffusion and perfusion.


Image: The FDA-cleared RAPID CTA identifies regions with reductions in blood flow that can indicate a large vessel occlusion within minutes. Photo: courtesy of Business Wire.